Oculis (NASDAQ:OCS) Sees Large Volume Increase – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS) shares saw unusually-strong trading volume on Tuesday . Approximately 1,245,505 shares were traded during mid-day trading, an increase of 274% from the previous session’s volume of 332,726 shares.The stock last traded at $28.2620 and had previously closed at $27.42.

Wall Street Analyst Weigh In

OCS has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd. HC Wainwright raised their target price on shares of Oculis from $42.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Wall Street Zen downgraded shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Lifesci Capital began coverage on shares of Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on shares of Oculis in a research note on Friday, December 19th. They issued an “overweight” rating and a $38.00 price objective for the company. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $43.50.

Oculis Stock Down 4.8%

The firm has a 50-day moving average of $26.63 and a two-hundred day moving average of $21.78. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -12.02 and a beta of 0.29. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative return on equity of 62.12% and a negative net margin of 8,173.41%. As a group, sell-side analysts anticipate that Oculis Holding AG will post -2.09 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Syquant Capital Sas purchased a new position in shares of Oculis during the 4th quarter valued at $3,849,000. China Universal Asset Management Co. Ltd. increased its position in Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Oculis during the 4th quarter worth about $9,862,000. HRT Financial LP purchased a new stake in shares of Oculis during the 4th quarter worth about $876,000. Finally, Bank of America Corp DE lifted its holdings in shares of Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.